1. Home
  2. LYFT vs BPMC Comparison

LYFT vs BPMC Comparison

Compare LYFT & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYFT
  • BPMC
  • Stock Information
  • Founded
  • LYFT 2007
  • BPMC 2008
  • Country
  • LYFT United States
  • BPMC United States
  • Employees
  • LYFT N/A
  • BPMC N/A
  • Industry
  • LYFT Business Services
  • BPMC Biotechnology: Pharmaceutical Preparations
  • Sector
  • LYFT Consumer Discretionary
  • BPMC Health Care
  • Exchange
  • LYFT Nasdaq
  • BPMC Nasdaq
  • Market Cap
  • LYFT N/A
  • BPMC 5.8B
  • IPO Year
  • LYFT 2019
  • BPMC 2015
  • Fundamental
  • Price
  • LYFT $13.00
  • BPMC $98.76
  • Analyst Decision
  • LYFT Buy
  • BPMC Buy
  • Analyst Count
  • LYFT 32
  • BPMC 21
  • Target Price
  • LYFT $16.59
  • BPMC $124.05
  • AVG Volume (30 Days)
  • LYFT 12.2M
  • BPMC 1.0M
  • Earning Date
  • LYFT 05-08-2025
  • BPMC 05-01-2025
  • Dividend Yield
  • LYFT N/A
  • BPMC N/A
  • EPS Growth
  • LYFT N/A
  • BPMC N/A
  • EPS
  • LYFT 0.06
  • BPMC N/A
  • Revenue
  • LYFT $5,786,016,000.00
  • BPMC $562,121,000.00
  • Revenue This Year
  • LYFT $15.04
  • BPMC $44.85
  • Revenue Next Year
  • LYFT $12.11
  • BPMC $32.06
  • P/E Ratio
  • LYFT $226.11
  • BPMC N/A
  • Revenue Growth
  • LYFT 31.39
  • BPMC 99.19
  • 52 Week Low
  • LYFT $8.93
  • BPMC $73.04
  • 52 Week High
  • LYFT $19.07
  • BPMC $121.90
  • Technical
  • Relative Strength Index (RSI)
  • LYFT 60.79
  • BPMC 62.93
  • Support Level
  • LYFT $12.31
  • BPMC $87.03
  • Resistance Level
  • LYFT $13.21
  • BPMC $104.86
  • Average True Range (ATR)
  • LYFT 0.46
  • BPMC 3.73
  • MACD
  • LYFT 0.16
  • BPMC 1.65
  • Stochastic Oscillator
  • LYFT 91.94
  • BPMC 71.75

About BPMC Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Share on Social Networks: